Price Hikes Protect Cephalon, Lining Up Nuvigil Ducks
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm to add sales reps after ending Takeda co-promotion deal.
You may also be interested in...
Panel COVERS Problems With Cephalon’s Fentora
Risk-management plan is “impressive,” but needs supporting evidence, FDA advisors say.
Amrix And Treanda Take-up Bodes Well For Cephalon
New drugs help firm move on from fading Actiq, beset by generic erosion.
FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash
Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.